|
T2649 |
Menin-MLL inhibitor MI-2
|
Menin-MLL Inhibitor,MI2,MI-2,Menin-MLL inhibitor 2,MI 2 |
Apoptosis
,
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
Menin-MLL inhibitor MI-2 (MI2) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM. |
|
T9399 |
Menin-MLL inhibitor 20
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
Menin-MLL inhibitor 20 is an irreversible inhibitor of menin-MLL interaction with antitumor activities. |
|
T2643 |
MI-3
|
Menin-MLL Inhibitor,Menin-MLL inhibitor 3,MI 3 |
Apoptosis
,
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-3 (Menin-MLL Inhibitor) (Menin-MLL Inhibitor) is an effective inhibitor of Menin-MLL interaction (IC50: 648 nM). |
|
T12002 |
Menin-MLL inhibitor 4
|
|
Others
|
|
Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction . |
|
T79737 |
Menin-MLL inhibitor 29
|
|
Epigenetic Reader Domain
|
|
Menin-MLL Inhibitor 29 (Compound C1) is a Menin-MLL protein-protein interaction (PPI) inhibitor that demonstrates high affinity to Menin with a dissociation constant (K D) of 138 nM and impedes Menin's interaction with M... |
|
T78151 |
Bleximenib oxalate
|
Menin-MLL inhibitor 24 oxalate |
Epigenetic Reader Domain
|
|
Menin-MLL Inhibitor 24 (compound A) oxalate, a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor, is utilized in cancer research [1]. |
|
T72360 |
Menin-MLL inhibitor 26
|
|
|
|
Menin-MLL inhibitor 26 is a Menin-MLL inhibitor. Menin-MLL inhibitor 26 also is an active reference. Menin-MLL inhibitor 26 can inhibits cell growth. Menin-MLL inhibitor 26 can be used for the research of leukemia . |
|
T79117 |
Menin-MLL inhibitor 27
|
|
Epigenetic Reader Domain
|
|
Menin-MLL inhibitor 27 effectively inhibits the interaction between Menin and MLL, serving as a potential tool in cancer research, particularly for acute myeloid leukemia (AML) [1]. |
|
T72135 |
(1s,4s)-Menin-MLL inhibitor-23
|
|
|
|
(1s,4s)-Menin-MLL Inhibitor-23, an enantiomer of Menin-MLL Inhibitor-23 (Example 99A), functions as an inhibitor of the menin-MLL interaction [1]. |
|
T13336 |
VTP50469
|
|
Apoptosis
,
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
VTP50469 is a highly selective and orally active inhibitor of Menin-MLL interaction( Ki: 104 pM) and has potently anti-leukemia activity. |
|
T12943 |
SNDX-5613
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias. |
|
T28036 |
MI-2-2
|
MI22,MI 2 2 |
Histone Methyltransferase
|
|
MI-2-2 is an inhibitor of bivalent protein-protein interaction between menin and MLL with an IC50 of 46 nM. MI-2-2 binds to menin with Kd of 22 nM. |
|
T69628 |
Iptacopan hydrochloride hydrate
|
|
|
|
Iptacopan hydrochloride hydrate is a highly potent and highly selective factor B inhibitor. |
|
T20705 |
Desmeninol
|
|
|
|
Desmeninol is an active endogenous metabolite, detected mainly in urine, and in cells located mainly in the cytoplasm and fat bodies. It is used as a catalyst, chlorinating agent, curing agent and stabilizer in organic s... |
|
T124063 |
Isochamaejasmenin B
|
|
|
|
Isochamaejasmenin B is a useful organic compound for research related to life sciences and the catalog number is T124063. |
|
T124064 |
Chamaejasmenin D
|
|
|
|
Chamaejasmenin D is a useful organic compound for research related to life sciences and the catalog number is T124064. |
|
T11925 |
M‑89
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia... |
|
T16072 |
MI-538
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM). |
|
TQ0069 |
MI-503
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-503 is a highly effective and orally bioavailable inhibitor of the menin-mLL interaction. |
|
TQ0058 |
MI-463
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-463 is a potent and orally bioavailable inhibitor of the menin-mLL interaction (IC50: 15.3 nM). |
|
T6889 |
MI-136
|
|
Apoptosis
,
Epigenetic Reader Domain
,
Androgen Receptor
|
|
MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced. |
|
T13336L |
VTP50469 fumarate
|
|
Others
|
|
VTP50469 fumarate is a highly selective and orally active inhibitor of Menin-MLL interaction (Ki: 104 pM), and has potently anti-leukemia activity. |
|
T39937 |
M-808
|
|
|
|
M-808 is a potent and efficacious covalent inhibitor, targeting the interaction between Menin and MLL. It demonstrates a high binding affinity with an IC50 value of 2.6 nM. |
|
T24471 |
MIV-6
|
|
|
|
MIV-6 is an inhibitor of the menin-mixed lineage leukemia interaction. |
|
T22978 |
MI-2 (hydrochloride)
|
|
Others
|
|
MI-2 (Menin-MLL Inhibitor) is an effective menin-MLL interaction inhibitor (IC50: 446 ± 28 nM). |
|
T69629 |
M‑89 MLL inhibitor
|
|
|
|
M‑89 is a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein−Protein Interaction (Kd = 1.4 nM; IC50 = 25nM). M-89 binds to menin with a Kd value of 1.4 nM and effectively engages cellular men... |
|
T61735 |
MI-1
|
|
|
|
MI-1 inhibits Menin-MLL interaction with an IC 50 of 1.9 μM [1]. |
|
T39584 |
MI-3454
|
|
|
|
MI-3454 is a highly potent, orally active, and selective inhibitor of the interaction between menin and MLL1, with an IC50 of 0.51 nM. This compound effectively inhibits the proliferation of leukemic cells and promotes t... |
|
T15831 |
M-525
|
|
Others
|
|
M-525 binds to menin (IC50: 3 nM) and achieves low nanomolar potencies in cell growth inhibition and in the suppression of MLL regulated gene expression in MLL leukemia cells. M-525 is a first-in-class, highly potent, ir... |
|
T24484 |
ML399
|
VU-0516340,VU 0516340,ML-399,VU0516340,ML 399 |
|
|
ML399 is the menin-- MLL interaction inhibitor that acts by demonstrating strong and selective effects in MLL leukemia cells and validating specific mechanism of action. |
|
T39938 |
M-1211
|
|
|
|
M 1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression. |
|
T24472 |
MIV-6R
|
MIV6R,VU05163101,VU0516310-1,VU0516310 1,MIV 6R |
|
|
MIV-6R is an inhibitor of the menin- MLL interaction that acts by demonstrating strong and selective effects in MLL leukemia cells and validating specific mechanisms of action. |
|
T39585 |
Ziftomenib
|
KO-539 |
Histone Methyltransferase
|
|
Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity and can be used to study leukemia. |
|
T27134 |
DCYM21
|
DC YM 21,DC-YM21,DCYM-21,DC_YM21,DC YM21 |
|
|
DCYM21 is an inhibitor of menin-MLL interaction. DCYM21 demonstrates potent and selective blockage of proliferation and induces both cell cycle arrest and differentiation of leukemia cells harboring MLL translocations. |
|
T24463 |
MI-1481
|
MI 1481 |
|
|
MI-1481 is an effective MML1 inhibitor (IC50: 3.6 nM). MI-1481 showed very potent inhibition of the menin-MLL1 interaction (IC50: 3.6 nM). MI-1481 also demonstrates pronounced activity in MLL leukemia cells and in vivo i... |
